- Home
- AMLX vs MGTX Comparison
AMLX vs MGTX Comparison
Compare AMLX & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMLX
- MGTX
- Stock Information
- Founded
- AMLX 2014
- MGTX 2015
- Country
- AMLX United States
- MGTX United States
- Employees
- AMLX N/A
- MGTX N/A
- Industry
- AMLX Biotechnology: Pharmaceutical Preparations
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMLX Health Care
- MGTX Health Care
- Exchange
- AMLX Nasdaq
- MGTX Nasdaq
- Market Cap
- AMLX 749.9M
- MGTX 670.2M
- IPO Year
- AMLX 2022
- MGTX N/A
- Fundamental
- Price
- AMLX $13.48
- MGTX $8.30
- Analyst Decision
- AMLX Strong Buy
- MGTX Strong Buy
- Analyst Count
- AMLX 7
- MGTX 2
- Target Price
- AMLX $15.14
- MGTX $24.00
- AVG Volume (30 Days)
- AMLX 2.0M
- MGTX 362.5K
- Earning Date
- AMLX 11-06-2025
- MGTX 11-12-2025
- Dividend Yield
- AMLX N/A
- MGTX N/A
- EPS Growth
- AMLX N/A
- MGTX N/A
- EPS
- AMLX N/A
- MGTX N/A
- Revenue
- AMLX N/A
- MGTX $37,917,000.00
- Revenue This Year
- AMLX N/A
- MGTX $144.79
- Revenue Next Year
- AMLX N/A
- MGTX $168.58
- P/E Ratio
- AMLX N/A
- MGTX N/A
- Revenue Growth
- AMLX N/A
- MGTX 366.84
- 52 Week Low
- AMLX $2.60
- MGTX $3.97
- 52 Week High
- AMLX $15.15
- MGTX $8.98
- Technical
- Relative Strength Index (RSI)
- AMLX 61.47
- MGTX 60.62
- Support Level
- AMLX $12.35
- MGTX $8.20
- Resistance Level
- AMLX $13.75
- MGTX $8.68
- Average True Range (ATR)
- AMLX 0.82
- MGTX 0.39
- MACD
- AMLX -0.22
- MGTX 0.04
- Stochastic Oscillator
- AMLX 41.86
- MGTX 73.57
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.